Jazz Pharmaceuticals (JAZZ) Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $4.6 billion for Q1 2026.

• In Q1 2026, Current Assets rose 11.03% year-over-year to $4.6 billion; the TTM figure through Mar 2026 stood at $4.6 billion (up 11.03% YoY), while the FY2025 annual figure was $4.2 billion, down 10.0% from the prior year.
• Current Assets was $4.6 billion for Q1 2026 at Jazz Pharmaceuticals, up from $4.2 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $4.6 billion in Q4 2024 to a low of $2.5 billion in Q1 2022.
• Historically, Current Assets has averaged $3.5 billion across 5 years, with a median of $3.4 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Current Assets fell 21.03% in 2022, then surged 35.27% in 2024.
• A 5-year view of Current Assets shows it stood at $2.6 billion in 2022, then soared by 31.82% to $3.4 billion in 2023, then soared by 34.74% to $4.6 billion in 2024, then slipped by 10.0% to $4.2 billion in 2025, then increased by 10.01% to $4.6 billion in 2026.
• The last three Current Assets figures came in at $4.6 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.